Transforming growth factors are a subset of polypeptide growth factors which help to regulate normal cell growth and differentiation. Epidermal growth factor (EGF) is an essential factor in the development of mammary glands in mice. ' The tumour tissue was stained with a monoclonal antibody to EGFR using an indirect peroxidase method. Frozen sections (4 gim) were cut at 4°C, then dried at room temperature for two hours, before fixing in 50:50 acetone:chloroform at 4'C for 10 minutes. Sections were incubated with the monoclonal anti-EGFR antibody (EGFR1) at a 1/100 dilution in 1/5 normal swine serum for 45 minutes. Rabbit anti-mouse peroxidase conjugate was then applied at a 1/50 dilution in 1/5 normal swine serum for 20 minutes. The sections were washed with TRIS-buffered saline between stages. Diaminobenzidine was used as the chromagen, with imidazole and copper sulphate enhancement. Haematoxylin was used as the counterstain. A section of normal skin was used as the positive control and omission of the primary antibody as the negative control.
Results were analysed by two observers independently according to the degree of tumour membrane staining and total amount of staining by allocating grades of 0, 1, 2, and 3, 0 being no detectable staining; 1 very faint cytoplasmic reactivity; 2 distinct cytoplasmic reactivity; and 3 strong cytoplasmic reactivity or membrane reactivity (fig 1) . For the purpose of this study 0 and 1 were regarded as negative and 2 and 3 as positive. It was felt this method was superior to radiological binding methods, because although subjective, it offered the (fig 3) . A Cox multivariate analysis was used to determine which of the variables studied had independent prognostic significance.'5 Lymph node stage, histological grade, tumour size, oestrogen receptor and progesterone receptor normal cellular growth and proliferation but also in as yet poorly understood ways in disease states, including cancer. The study was undertaken to evaluate the prognostic potential of measurement of EGFR in primary breast cancer. An immunocytochemical method was chosen instead of -a biochemical method, because of its ability to identify tumour positivity at a cellular level, excluding the influence of variance of tumour tissue cellularity. The prevalence of EGFR positivity of 14% is lower than that in other studies-29%2 and 26%.6 In our series only patients with primary operable breast cancer and not those with advanced disease were studied. This selection process may have had an influence on the number of positive cases. Only tumours with unequivocal distinct cytoplasmic or membrane reactivity were regarded as positive.
We have shown that there is a strong relation between EGFR expression and subsequent disease free interval. This concurs with the finding of Sainsbury et al in a study of 135 breast cancers.'0 They also found a highly significant correlation between EGFR positivity and both early relapse and overall patient survival. We have not yet analysed survival data as the follow up of these patients is still limited.
EGFR positivity did not correlate in this therapy or hormonal manipulation. It must be stated, however, that before this could be implemented this index would require confirmation in a prospective study in a larger group of patients.
There has been considerable recent interest in the prognostic effect of the oncoprotein cerb B2 in breast carcinoma.'9 CerbB2 is a membrane receptor which has a striking sequence homology with EGFR.20 Both EGFR expression and cerbB2 oncoprotein immunoreactivity can provide prognostic information in breast cancer, but to our knowledge there is no recognised association between these two similar membrane receptors. Further work is needed to examine any possible relation between them and their combined role in the management of breast cancer.
